Supernus Pharmaceuticals (SUPN) Projected to Post Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is expected to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.46 per share and revenue of $155.27 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $39.11 on Tuesday. The firm has a market capitalization of $2.16 billion, a P/E ratio of 36.55 and a beta of 0.90. The stock has a 50-day simple moving average of $37.58 and a two-hundred day simple moving average of $35.21. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald initiated coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target for the company.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.